From Our Partners
Wednesday, June 29, 2022
News on Pathogens and Preparedness
Global Biodefense
  • Featured
  • COVID-19
  • Funding
  • Directory
  • Jobs
  • Events
  • Subscribe
No Result
View All Result
  • Featured
  • COVID-19
  • Funding
  • Directory
  • Jobs
  • Events
  • Subscribe
No Result
View All Result
Global Biodefense
No Result
View All Result
Home Medical Countermeasures

FDA Approves First Antitoxin to Neutralize All 7 Botulism Serotypes

by Global Biodefense Staff
March 25, 2013

Botulinum toxinThe U.S. Food and Drug Administration last week announced that it has approved Botulism Antitoxin Heptavalent (A, B, C, D, E, F, G)-(Equine), the only product to neutralize all known botulinum nerve toxin serotypes that cause deadly botulism.

Development of the antitoxin began over 10 years ago, and in 2006 the drug candidate became one of the first medical countermeasures to receive support for advanced development and procurement under Project BioShield. Cangene Corporation of Winnipeg, Canada manufactures the product.

The Biomedical Advanced Research and Development Authority (BARDA), which manages Project BioShield, is procuring the drug so that it can be readily available from the Strategic National Stockpile. The Cangene drug holds the distinction of being the first botulism product supported under Bioshield to be approved by the FDA, as well being the second antitoxin to address a bioterrorism threat to be supported under Project BioShield and approved by FDA.

Botulinum nerve toxins are among the most potent toxins known, and if patients are left untreated, the toxins may cause muscular paralysis that can lead to death. Botulism results from ingesting or inhaling a botulinum nerve toxin, or by exposure arising from toxin secreted by Clostridium bacteria in a wound or the intestine.

Botulinum nerve toxins also can be used as a bioweapon and are classified a Category A Priority Pathogen on the federal Select Agent list. A biological terrorism event with botulinum nerve toxins would require a rapid health response with potentially little time to determine which botulism toxin was used. Because this new drug can be used to treat all known botulinum nerve toxin serotypes, the drug can be used readily in this type of public health emergency. 

The new heptavalent antitoxin is the only product available for the treatment of botulism in adults, and for cases of infant botulism caused by nerve toxins other than types A and B. This antitoxin also represents the first approval of a plasma derivative using the FDA Animal Rule.

Sources: FDA News, PHE.gov

From Our Partners
Tags: AntitoxinsASPRBARDABioterrorismBotulinum NeurotoxinHHSStrategic National Stockpile

Related Posts

UK Health Security Agency Widens Monkeypox Vaccine Umbrella for Outbreak Control
Medical Countermeasures

UK Health Security Agency Widens Monkeypox Vaccine Umbrella for Outbreak Control

June 21, 2022
Biodefense Industry News
Industry News

Tonix Pharmaceuticals Opens Advanced Development Center for Vaccine Programs

June 20, 2022
Chronic Wasting Disease: The Fatal Prion Infection Killing Elk and Deer in North America
Infectious Diseases

Chronic Wasting Disease: The Fatal Prion Infection Killing Elk and Deer in North America

June 10, 2022
Monkeypox Cases Prompt Additional Contracts for Bavarian Nordic Vaccine
Medical Countermeasures

Monkeypox Cases Prompt Additional Contracts for Bavarian Nordic Vaccine

May 30, 2022
Load More

Latest News

Poliovirus Detected in London Sewage: Response Measures Emphasize Wastewater Surveillance and Vaccination Gaps

Poliovirus Detected in London Sewage: Response Measures Emphasize Wastewater Surveillance and Vaccination Gaps

June 22, 2022
Monkeypox Diagnostics: CDC Authorizes Five Commercial Lab Companies

Monkeypox Diagnostics: CDC Authorizes Five Commercial Lab Companies

June 22, 2022
UK Health Security Agency Widens Monkeypox Vaccine Umbrella for Outbreak Control

UK Health Security Agency Widens Monkeypox Vaccine Umbrella for Outbreak Control

June 21, 2022
Influenza Research

New Way to Identify Influenza A Virus Lights Up When Specific Virus Targets are Present

June 20, 2022

Subscribe

  • About
  • Contact
  • Privacy
  • Subscribe

© 2022 Stemar Media Group LLC

No Result
View All Result
  • Featured
  • COVID-19
  • Funding
  • Directory
  • Jobs
  • Events
  • Subscribe

© 2022 Stemar Media Group LLC